etodolac has been researched along with Cholangitis in 1 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Cholangitis: Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Etodolac is expected to prevent secondary biliary carcinogenesis caused by persistent reflux cholangitis after bilioenterostomy." | 3.80 | A selective cyclooxygenase-2 inhibitor (Etodolac) prevents spontaneous biliary tumorigenesis in a hamster bilioenterostomy model. ( Adachi, T; Eguchi, S; Hirabaru, M; Kitasato, A; Kuroki, T; Ono, S; Takatsuki, M; Tanaka, T; Tsuneoka, N, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kitasato, A | 1 |
| Kuroki, T | 1 |
| Adachi, T | 1 |
| Ono, S | 1 |
| Tanaka, T | 1 |
| Tsuneoka, N | 1 |
| Hirabaru, M | 1 |
| Takatsuki, M | 1 |
| Eguchi, S | 1 |
1 other study available for etodolac and Cholangitis
| Article | Year |
|---|---|
A selective cyclooxygenase-2 inhibitor (Etodolac) prevents spontaneous biliary tumorigenesis in a hamster bilioenterostomy model.
Topics: Animals; Anticarcinogenic Agents; Bile Ducts; Biliary Tract Neoplasms; Biliary Tract Surgical Proced | 2014 |